Amgen's Q3 results show solid revenue and EPS growth, coupled with a strategic acquisition that enhances their rare disease portfolio. The raised 2023 revenue guidance and strong performance of key products like Tezspire likely boost investor confidence, despite increased costs from the Horizon acquisition. Overall, the stock is expected to experience a positive short-term impact.

[1]